A joint research team of the Korea Advanced Institute of Science and Technology (KAIST) and domestic biotechnology firm Neogenlogic has developed a new artificial intelligence (AI) model that can help produce a whole new type of "personalised" cancer vaccine, the joint team said on Friday. 

The new AI platform helps identify neoantigens unique to each cancer patient that can train the patient's immune system, and thus prevent recurrence of the illness, reports Yonhap news agency.